Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Determination 2 in Newly Diagnosed Multiple Myeloma
NCT07624513Phase 3Recruiting
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Aug 2026
- Primary completion
- Oct 2033
- Countries
- 1
01
Overview
A Phase 3 trial of isatuximab, iberdomide, linvoseltamab in multiple myeloma (MM), sponsored by Dana-Farber Cancer Institute. Started Aug 2026; status: recruiting.
02
Drugs
isatuximabiberdomidelinvoseltamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT07624513.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07624513.